ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.
暂无分享,去创建一个
D. Zheng | A. Sboner | G. Wang | Y. Whang | H. Earp | Ping Wang | R. Bareja | Ling Cai | Yilin Zhao | Yi-Hsuan Tsai | H. Fan | Dongxu Li | Jun Wang | E. M. Wilson | Rui Lu | J. Parker
[1] S. Mirarab,et al. Sequence Analysis , 2020, Encyclopedia of Bioinformatics and Computational Biology.
[2] D. Tindall,et al. Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer , 2018, Nucleic acids research.
[3] G. Wang,et al. Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia , 2017, Front. Oncol..
[4] Chien-Feng Li,et al. Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist , 2017, Oncogene.
[5] Henry W. Long,et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.
[6] M. Rubin,et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.
[7] D. Zheng,et al. Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development. , 2016, Cancer cell.
[8] J. Lindberg,et al. Gene regulatory mechanisms underpinning prostate cancer susceptibility , 2016, Nature Genetics.
[9] J. Shendure,et al. Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer , 2016, Nature Medicine.
[10] Matteo Benelli,et al. Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.
[11] A. Chinnaiyan,et al. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer , 2016, Molecular Cancer Research.
[12] V. Arora,et al. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.
[13] Steven J. M. Jones,et al. The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.
[14] Henry W. Long,et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis , 2015, Nature Genetics.
[15] Ben S. Wittner,et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance , 2015, Science.
[16] S. Gambhir,et al. Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes. , 2015, Cancer research.
[17] Michael D. Nyquist,et al. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies , 2015, Nucleic acids research.
[18] Le Zhang,et al. ZNF32 inhibits autophagy through the mTOR pathway and protects MCF-7 cells from stimulus-induced cell death , 2015, Scientific Reports.
[19] D. Tindall,et al. The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. , 2015, The Journal of urology.
[20] B. Garcia,et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. , 2014, Blood.
[21] P. Canoll,et al. Zfx facilitates tumorigenesis caused by activation of the Hedgehog pathway. , 2014, Cancer research.
[22] W. Isaacs,et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.
[23] Zhaohui S. Qin,et al. Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.
[24] H. Kung,et al. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model , 2014, Oncogene.
[25] L. Mirny,et al. ZFX controls propagation and prevents differentiation of acute T-lymphoblastic and myeloid leukemia. , 2014, Cell reports.
[26] D. Zheng,et al. Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade , 2013, Cell.
[27] M. Hung,et al. Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression , 2013, Cell.
[28] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[29] D. Zheng,et al. An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting. , 2013, Molecular cell.
[30] K. Silverstein,et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. , 2013, Cancer research.
[31] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[32] Mark Trifiro,et al. The androgen receptor gene mutations database: 2012 update , 2012, Human mutation.
[33] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[34] W. Isaacs,et al. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities , 2011, The Prostate.
[35] S. Lowe,et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.
[36] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[37] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[38] P. Stattin,et al. Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival , 2011, PloS one.
[39] Philip Machanick,et al. MEME-ChIP: motif analysis of large DNA datasets , 2011, Bioinform..
[40] Raymond K. Auerbach,et al. A User's Guide to the Encyclopedia of DNA Elements (ENCODE) , 2011, PLoS biology.
[41] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer , 2011, Nature Biotechnology.
[42] Tao Ye,et al. seqMINER: an integrated ChIP-seq data interpretation platform , 2010, Nucleic acids research.
[43] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[44] N. Socci,et al. Inaugural Article: Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor , 2010 .
[45] Derek Y. Chiang,et al. MapSplice: Accurate mapping of RNA-seq reads for splice junction discovery , 2010, Nucleic acids research.
[46] P. Nelson,et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. , 2010, The Journal of clinical investigation.
[47] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[48] C. Glass,et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.
[49] Simon Anders,et al. Differential expression analysis for sequence count data , 2010, Genome Biology.
[50] Richard Durbin,et al. Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..
[51] D. McDonnell,et al. The homeodomain protein HOXB13 regulates the cellular response to androgens. , 2009, Molecular cell.
[52] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[53] H. Scher,et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.
[54] Dinshaw J. Patel,et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger , 2009, Nature.
[55] Zhiyong Guo,et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.
[56] S. Varambally,et al. Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.
[57] Clifford A. Meyer,et al. Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.
[58] D. Tindall,et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.
[59] N. D. Clarke,et al. Integration of External Signaling Pathways with the Core Transcriptional Network in Embryonic Stem Cells , 2008, Cell.
[60] P. Nelson,et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.
[61] Clifford A. Meyer,et al. FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription , 2008, Cell.
[62] G. Wang,et al. NUP98–NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis , 2007, Nature Cell Biology.
[63] Leonid A. Mirny,et al. Zfx Controls the Self-Renewal of Embryonic and Hematopoietic Stem Cells , 2007, Cell.
[64] J. Mesirov,et al. From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .
[65] M. Becich,et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] Jorma Isola,et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.
[67] F. S. French,et al. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. , 1995, Molecular endocrinology.
[68] A. Schneider-Gädicke,et al. Putative transcription activator with alternative isoforms encoded by human ZFX gene , 1989, Nature.
[69] A. Sboner,et al. ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 (AR-V7) in castrate-resistant prostate cancer , 2018 .
[70] R. Vessella,et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.
[71] R. Vessella,et al. Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.
[72] Claude-Alain H. Roten,et al. Theoretical and practical advances in genome halving , 2004 .